FORTY SEVEN INC. overview

-- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML -- -- Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and Rocket Pharmaceuticals to Expand Development Program -- -- Gilead Acquisition of Forty Seven Expected to Close in 2Q 2020 -- MENLO PARK, Calif., March 20, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate...

MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV) and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 (anti-cKIT antibody) plus magrolimab (anti-CD47 antibody), with Rocket’s ex vivo lentiviral vector hematopoietic stem cell (LVV HSC) gene therapy, RP-L102. The initial...

MENLO PARK, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced its participation in the following upcoming investor conferences: Cowen 40 th Annual Health Care Conference on Tuesday, March 3, 2020 at 8:40 a.m. ET in Boston, MA. 32 nd Annual ROTH Conference on Monday, March 16, 2020 at 10:00 a.m. PT (1:00 p.m. ET) in Dana Point, CA....

MENLO PARK, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced its participation in the following upcoming investor conferences: Guggenheim Healthcare Talks | Oncology Day on Thursday, February 13, 2020 at 11:30 a.m. ET in New York, NY. 9 th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 11:30 a.m....

-- Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 -- -- Updated Data from Ongoing Phase 1b Trial in Higher-Risk MDS and AML Expected Mid-Year 2020 -- -- Initial Data from Phase 3 Trial in DLBCL Expected in 4Q 2020 -- -- FSI-174 and FSI-189 Expected to Enter Phase 1 in 1Q and 2Q 2020, Respectively -- -- FDA Granted Orphan Drug Designation for Magrolimab in MDS -- MENLO PARK, Calif., Jan....

MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public offering of 5,589,000 shares of common stock, including 729,000 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. Gross proceeds from the offering, before underwriting discounts and commissions and offering expenses, were approximately $195.6...

MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten public offering of 4,860,000 shares of its common stock at a price to the public of $35.00 per share. Gross proceeds to Forty Seven from the offering are expected to be $170.1 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common...

MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced that it has commenced an underwritten public offering of $140,000,000 of shares of its common stock. All of the shares of common stock are being offered by Forty Seven. In connection with this offering, Forty Seven expects to grant the underwriters a 30-day option to purchase up to $21,000,000 of additional shares of common stock. Morgan Stanley & Co....